Skip to main content

Advertisement

SpringerLink
Log in

TOXICAN: a guide for grading dermatological adverse events of cancer treatments

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

The dermatological toxicity of cancer treatments is frequent and sometimes debilitating. Its reference classification, the NCI-CTCAE (National Cancer Institute–Common Terminology Criteria for Adverse Events), is sometimes difficult to use and does not include yet the newest toxicities. Our objective was to create a guide, TOXICAN, based on the CTCAE, which is easy to use in everyday practice and which facilitates the recognition and grading of these dermatological toxicities.

Methods

This guide was developed by a working group (“GESTIM”) comprising oncodermatologists, allergists, pathologists, and researchers from Nantes University Hospital. It was based on the dermatological toxicities found in the CTCAE and adapted to daily practice. These toxicities were grouped into categories and associated with photographs of typical cases to aid recognition. A simplified grading scale derived from the CTCAE was also created. This booklet was validated by means of user evaluation, and then the Delphi consensus method.

Results

We selected 32 dermatological toxicities, including 12 created by our group, sorted into 7 categories: skin rash, dry skin/pruritus, hyperkeratotic papules, palmoplantar changes, hair and nail changes, mucosal changes, and others. Our simplified grading scale only differed from the CTCAE for one item, urticaria. Three items were modified after evaluation by the user group and 11 after application of the Delphi method.

Conclusion

The objective of our practical guide is to facilitate the use of the CTCAE for recognizing and grading dermatological toxicity of cancer treatments in order to provide optimal guidance for therapeutic adaptations. Its impact on clinical practice remains to be evaluated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3):176–181

    Article  PubMed  Google Scholar 

  2. Atkinson TM, Li Y, Coffey CW, Sit L, Shaw M, Lavene D, Bennett AV, Fruscione M, Rogak L, Hay J, Gonen M, Schrag D, Basch E (2012) Reliability of adverse symptom event reporting by clinicians. Qual Life Res 21(7):1159–1164

    Article  PubMed  Google Scholar 

  3. Palazzi M, Tomatis S, Orlandi E, Guzzo M, Sangalli C, Potepan P, Fantini S, Bergamini C, Gavazzi C, Licitra L, Scaramellini G, Cantu G, Olmi P (2008) Effects of treatment intensification on acute local toxicity during radiotherapy for head and neck cancer: prospective observational study validating CTCAE, version 3.0, scoring system. Int J Radiat Oncol Biol Phys 70(2):330–337

    Article  PubMed  Google Scholar 

  4. Jiang G, Wang L, Liu H, Solbrig HR, Chute CG (2013) Building a knowledge base of severe adverse drug events based on AERS reporting data using semantic web technologies. Stud Health Technol Inform 192:496–500

    PubMed  Google Scholar 

  5. Bergman H, Walton T, Del Bel R, Seki JT, Rafii A, Xu W, Koren G, Shear N, Krzyzanowska MK, Howell D, Liu G (2014) Managing skin toxicities related to panitumumab. J Am Acad Dermatol 71(4):754–759

    Article  PubMed  CAS  Google Scholar 

  6. Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, Epstein JB, Barasch A, Einhorn L, Wagner L, West DP, Rapoport BL, Kris MG, Basch E, Eaby B, Kurtin S, Olsen EA, Chen A, Dancey JE, Trotti A (2010) A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 18(4):509–522

    Article  PubMed  Google Scholar 

  7. Chan A, Tan EH (2011) How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors? Support Care Cancer 19(10):1667–1674

    Article  PubMed  Google Scholar 

  8. Sibaud V, Delord JP, Robert C (2015) Dermatology and anticancer therapies: practical handbook. Editions Privat, Toulouse

    Google Scholar 

  9. Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME (2007) Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12(5):610–621

    Article  PubMed  CAS  Google Scholar 

  10. Gonzalez-Sanchis A, Vicedo-Gonzalez A, Brualla-Gonzalez L, Gordo-Partearroyo JC, Inigo-Valdenebro R, Sanchez-Carazo J, Granero-Cabanero D, Rosello-Ferrando J, Lopez-Torrecilla J (2014) Looking for complementary alternatives to CTCAE for skin toxicity in radiotherapy: quantitative determinations. Clin Transl Oncol 16(10):892–897

    Article  PubMed  CAS  Google Scholar 

  11. Liu YJ, Zhu GP, Guan XY (2012) Comparison of the NCI-CTCAE version 4.0 and version 3.0 in assessing chemoradiation-induced oral mucositis for locally advanced nasopharyngeal carcinoma. Oral Oncol 48(6):554–559

    Article  PubMed  CAS  Google Scholar 

  12. Deng J, Ridner SH, Dietrich MS, Wells N, Murphy BA (2013) Assessment of external lymphedema in patients with head and neck cancer: a comparison of four scales. Oncol Nurs Forum 40(5):501–506

    Article  PubMed  Google Scholar 

  13. Eisbruch A, Rhodus N, Rosenthal D, Murphy B, Rasch C, Sonis S, Scarantino C, Brizel D (2003) How should we measure and report radiotherapy-induced xerostomia? Semin Radiat Oncol 13(3):226–234

    Article  PubMed  Google Scholar 

  14. Peuvrel L, Dreno B (2014) Dermatological toxicity associated with targeted therapies in cancer: optimal management. Am J Clin Dermatol 15(5):425–444

    Article  PubMed  Google Scholar 

  15. Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Murphy BA (2011) Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 19(8):1079–1095

    Article  PubMed  PubMed Central  Google Scholar 

  16. Russo AL, Taghian AG (2013) Fat necrosis of the breast in the accelerated partial breast irradiation era: the need for a universal grading system. Breast Cancer Res Treat 140(1):1–11

    Article  PubMed  CAS  Google Scholar 

  17. Fine LM, Bernstein JA (2015) Urticaria guidelines: consensus and controversies in the European and American guidelines. Curr Allergy Asthma Rep 15(6):30

    Article  PubMed  Google Scholar 

  18. Williams KW, Sharma HP (2015) Anaphylaxis and urticaria. Immunol Allergy Clin N Am 35(1):199–219

    Article  Google Scholar 

  19. Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A (2015) Cutaneous adverse effects of targeted therapies: part I: inhibitors of the cellular membrane. J Am Acad Dermatol 72(2):203–218 quiz 219-220

    Article  PubMed  CAS  Google Scholar 

  20. Zenda S, Ota Y, Tachibana H, Ogawa H, Ishii S, Hashiguchi C, Akimoto T, Ohe Y, Uchitomi Y (2016) A prospective picture collection study for a grading atlas of radiation dermatitis for clinical trials in head-and-neck cancer patients. J Radiat Res 57(3):301–306

    Article  PubMed  PubMed Central  Google Scholar 

  21. Lencioni A, Hutchins L, Annis S, Chen W, Ermisoglu E, Feng Z, Mack K, Simpson K, Lane C, Topaloglu U (2015) An adverse event capture and management system for cancer studies. BMC Bioinformatics 16(Suppl 13):S6

    Article  PubMed  PubMed Central  Google Scholar 

  22. Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, Mendoza TR, Hay J, Atkinson TM, Abernethy AP, Bruner DW, Cleeland CS, Sloan JA, Chilukuri R, Baumgartner P, Denicoff A, St Germain D, O'Mara AM, Chen A, Kelaghan J, Bennett AV, Sit L, Rogak L, Barz A, Paul DB, Schrag D (2014) Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 106(9)

  23. Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, Atkinson TM, Bennett AV, Denicoff AM, O'Mara AM, Li Y, Clauser SB, Bryant DM, Bearden JD 3rd, Gillis TA, Harness JK, Siegel RD, Paul DB, Cleeland CS, Schrag D, Sloan JA, Abernethy AP, Bruner DW, Minasian LM, Basch E (2015) Validity and reliability of the US National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol 1(8):1051–1059

    Article  PubMed  PubMed Central  Google Scholar 

  24. Hay JL, Atkinson TM, Reeve BB, Mitchell SA, Mendoza TR, Willis G, Minasian LM, Clauser SB, Denicoff A, O'Mara A, Chen A, Bennett AV, Paul DB, Gagne J, Rogak L, Sit L, Viswanath V, Schrag D, Basch E (2014) Cognitive interviewing of the US National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Qual Life Res 23(1):257–269

    Article  PubMed  Google Scholar 

  25. Kluetz PG, Chingos DT, Basch EM, Mitchell SA (2016) Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Am Soc Clin Oncol Educ Book 35:67–73

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We sincerely thank the following for their reviewing and their comments on the guide: Hélène Aubert, Sébastien Barbarot, Claire Bernier, Justine Daguzé, Brigitte Dréno, Hervé Dutartre, Cécile Frénard, Amir Khammari, Clémence Mesnard, Marie Le Moigne, Louise Muguet, Gaëlle Quéreux, Mélanie Saint-Jean, Diane Sellah, Anouk Soenen, Jean-François Stalder, Marie-Hélène Tessier, Morgane Vourch Jourdain.

Author information

Authors and Affiliations

  1. Department of Dermatology, CHU Nantes, CIC 1413, CRCINA INSERM 1232, Nantes, France

    L. Peuvrel, J. Cassecuel, C. Bernier, G. Quéreux, M. Saint-Jean, M. Le Moigne, C. Frénard, A. Khammari & B. Dréno

Authors
  1. L. Peuvrel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Cassecuel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Bernier
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Quéreux
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Saint-Jean
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Le Moigne
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C. Frénard
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Khammari
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. B. Dréno
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments

Corresponding author

Correspondence to B. Dréno.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

ESM 1

Final version of our guide “TOXICAN, a grading guide of dermatological adverse events of cancer treatments” (PDF 917 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Peuvrel, L., Cassecuel, J., Bernier, C. et al. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer 26, 2871–2877 (2018). https://doi.org/10.1007/s00520-018-4153-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-018-4153-x

Keywords

Search

Navigation